Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 9/2007

01-09-2007 | Therapy In Practice

Membranous Nephropathy in the Older Adult

Epidemiology, Diagnosis and Management

Authors: Dr Jeroen K. J. Deegens, Jack F. M. Wetzels

Published in: Drugs & Aging | Issue 9/2007

Login to get access

Abstract

Membranous nephropathy is the most important cause of the nephrotic syndrome in elderly patients (aged >65 years). The clinical presentation is similar in older and younger patients, although elderly patients more often present with renal failure. Notably, glomerular filtration rate (GFR) is usually lower in the elderly due to the physiological decline in GFR after the age of 30 years. Secondary causes, especially malignancies, are more common in older patients with membranous nephropathy. Therefore, elderly patients should undergo a thorough examination to exclude a secondary cause. The prognosis of elderly patients with idiopathic membranous nephropathy is not very different from that of younger patients. All elderly patients should receive symptomatic treatment aimed at reducing hypertension, oedema, proteinuria and hyperlipidaemia. It is recommended that elderly patients with a low serum albumin (<2 g/dL) receive prophylactic anticoagulation because of a high risk for thrombosis. Immunosuppressive therapy should be reserved for elderly patients at high risk of progression to end-stage renal disease because the elderly are particularly prone to the adverse effects and infectious complications of immunosuppressive therapy. High-risk elderly patients are characterised by renal insufficiency (GFR <45 mL/min/1.73m2), an increase in serum creatinine of >25% or a severe persistent nephrotic syndrome not responding to symptomatic treatment. In addition, elderly patients with a relatively normal GFR (≥45 mL/min/1.73m2) and high urinary excretion of β2-microglobulin and IgG are also at increased risk of developing end-stage renal disease; however, the deterioration in renal function is usually a slow process. Therefore, such patients benefit from immunosuppressive therapy only if their life expectancy is good. If immunosuppressive therapy is started, first-line treatment consists of prednisone and cyclophosphamide. If cyclophosphamide is contraindicated or fails to induce a remission, ciclosporin could be used. Treatment with ciclosporin should be limited to patients with a relatively normal renal function (GFR >60 mL/min/1.73m2) in view of its nephrotoxicity in patients with renal dysfunction.
Literature
1.
2.
Stengel B, Billon S, Van Dijk PC, et al. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990–1999. Nephrol Dial Transplant 2003 Sep; 18(9): 1824–33PubMedCrossRef
3.
Gansevoort RT, van der Heij B, Stegeman CA, et al. Trends in the incidence of treated end-stage renal failure in The Netherlands: hope for the future? Kidney Int Suppl 2004; (92): S7–10
4.
Cameron JS. Nephrotic syndrome in the elderly. Semin Nephrol 1996 Jul; 16(4): 319–29PubMed
5.
Vendemia F, Gesualdo L, Schena FP, et al. Epidemiology of primary glomerulonephritis in the elderly: report from the Italian Registry of Renal Biopsy. J Nephrol 2001 Sep; 14(5): 340–52PubMed
6.
Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002 Jun 27; 346(26): 2053–60PubMedCrossRef
7.
Debiec H, Nauta J, Coulet F, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004 Oct 2; 364(9441): 1252–9PubMedCrossRef
8.
Glassock RJ. Secondary membranous glomerulonephritis. Nephrol Dial Transplant 1992; 7Suppl. 1: 64–71PubMed
9.
Verger MF, Droz D, Vantelon J. Autoimmune thyroid diseases associated with glomerular nephropathy: 3 cases. Presse Med 1983 Jan 15; 12(2): 83–6PubMed
10.
Lefaucheur C, Stengel B, Nochy D, et al. Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 2006 Oct; 70(8): 1510–7PubMedCrossRef
11.
Deegens J, Wetzels J. Diagnosis and treatment of primary glomerular diseases: membranous nephropathy, focal segmental glomerulosclerosis and IgA nephropathy. Minerva Urol Nefrol 2005 Sep; 57(3): 211–36PubMed
12.
Radford Jr MG, Holley KE, Grande JP, et al. Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 1996 Aug 14; 276(6): 466–9PubMedCrossRef
13.
Textor SC, Gephardt GN, Bravo EL, et al. Membranous glomerulopathy associated with captopril therapy. Am J Med 1983 Apr; 74(4): 705–12PubMedCrossRef
14.
O’Callaghan CA, Hicks J, Doll H, et al. Characteristics and outcome of membranous nephropathy in older patients. Int Urol Nephrol 2002 Mar; 33(1): 157–65PubMedCrossRef
15.
Rollino C, Roccatello D, Vallero A, et al. Membranous glomerulonephritis in the elderly: is therapy still worthwhile? Geriatr Nephrol Urol 1995 Aug; 5(2): 97–104CrossRef
16.
Zent R, Nagai R, Cattran DC. Idiopathic membranous nephropathy in the elderly: a comparative study. Am J Kidney Dis 1997 Feb; 29(2): 200–6PubMedCrossRef
17.
Ponticelli C, Passerini P, Cresseri D. Primary glomerular diseases in the elderly. Geriatr Nephrol Urol 1996 Jan; 6(2): 105–12CrossRef
18.
Davison AM, Johnston PA. Glomerulonephritis in the elderly. Nephrol Dial Transplant 1996; 11Suppl. 9: 34–7PubMedCrossRef
19.
Mak SK, Lo KY, Wong CY, et al. Treatment with cyclophosphamide in elderly-onset nephrotic syndrome. Nephron Clin Pract 2005; 101(1): c25–32PubMedCrossRef
20.
Johnston PA, Brown JS, Davison AM. The nephrotic syndrome in the elderly: clinico-pathological correlations in 317 patients. Geriatr Nephrol Urol 1992; 2(2): 85–90CrossRef
21.
Glassock RJ. Glomerular disease in the elderly population. Geriatr Nephrol Urol 1998; 8(3): 149–54PubMedCrossRef
22.
Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 2004 Mar; 19(3): 574–9PubMedCrossRef
23.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41PubMedCrossRef
24.
Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol 2000; 11: A0828
25.
Levey AS, Coresh J, Greene T, et al. Expressing the MDRD study equitation for estimating GFR with IDMS traceable (gold standard) serum creatinine values [abstract]. J Am Soc Nephrol 2005 Oct 1; 16: 69A
26.
Branten AJ, Vervoort G, Wetzels JF. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant 2005 Apr; 20(4): 707–11PubMedCrossRef
27.
Cirillo M, Laurenzi M, Mancini M, et al. Low glomerular filtration in the population: prevalence, associated disorders, and awareness. Kidney Int 2006 Aug; 70(4): 800–6PubMedCrossRef
28.
Branten AJ, du Buf-Vereijken PW, Klasen IS, et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005 Jan; 16(1): 169–74PubMedCrossRef
29.
Tu WH, Petitti DB, Biava CG, et al. Membranous nephropathy: predictors of terminal renal failure. Nephron 1984; 36(2): 118–24PubMedCrossRef
30.
31.
Davison AM, Cameron JS, Kerr DN, et al. The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol 1984 Aug; 22(2): 61–7PubMed
32.
Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993 Jul 8; 329(2): 85–9PubMedCrossRef
33.
Reichert LJM, Koene RAP, Wetzels JFM. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis 1998 Jan; 31(1): 1–11PubMedCrossRef
34.
Anderson S, Brenner BM. The aging kidney: structure, function, mechanisms, and therapeutic implications. J Am Geriatr Soc 1987 Jun; 35(6): 590–3PubMed
35.
Anderson S, Brenner BM. Effects of aging on the renal glomerulus. Am J Med 1986 Mar; 80(3): 435–42PubMedCrossRef
36.
Pei Y, Cattran DC, Greenwood C, et al. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992; 42: 960–6PubMedCrossRef
37.
Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 2005 May; 16(5): 1188–94PubMedCrossRef
38.
Bazzi C, Petrini C, Rizza V, et al. Urinary excretion of IgG and alpha(l)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am J Kidney Dis 2001 Aug; 38(2): 240–8PubMedCrossRef
39.
Reichert LJM, Koene RAP, Wetzels JFM. Urinary excretion of β2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J Am Soc Nephrol 1995 Dec 1; 6(6): 1666–9PubMed
40.
Reichert LJM, Koene RAP, Wetzels JFM. Urinary IgG excretion as a prognostic factor in idiopathic membranous nephropathy. Clin Nephrol 1997 Aug; 48(2): 79–84PubMed
41.
42.
43.
O’Meara Y, Levinne J. Management of complications of nephrotic syndrome. In: Brady H, Wilcox C, editors. Therapy in nephrology and hypertension. 2nd ed. London: Elsevier Science, 2003: 271–81
44.
K/DOQI clinical practice guidelines in hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004 May; 43Suppl. 1: 183–205
45.
The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nephrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997 Jun; 349(9069): 1857–63CrossRef
46.
Heeg JE, de Jong PE, van der Hem GK, et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989 Aug; 36(2): 272–9PubMedCrossRef
47.
du Buf-Vereijken P, Branten A, Wetzels J. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am J Kidney Dis 2005 Dec 1; 46(6): 1012–29PubMedCrossRef
48.
Troyanov S, Wall CA, Miller JA, et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004 Sep; 66(3): 1199–205PubMedCrossRef
49.
Praga M, Hernandez E, Montoyo C, et al. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992 Sep; 20(3): 240–8PubMed
50.
Ruggenenti P, Mise N, Pisoni R, et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003 Feb 4; 107(4): 586–92PubMedCrossRef
51.
Gansevoort RT, Heeg JE, Dikkeschei FD, et al. Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 1994; 9(3): 244–50PubMed
52.
Gansevoort R, Heeg J, Vriesendorp R. Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy. Nephrol Dial Transplant 1992; 7Suppl. 1: 91–6PubMed
53.
de Sain-van der Velden MG, Kaysen GA, Barrett HA, et al. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 1998 Apr; 53(4): 994–1001PubMedCrossRef
54.
Wanner C, Rader D, Bartens W, et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993 Aug 15; 119(4): 263–9PubMed
55.
Ordonez JD, Hiatt RA, Killebrew EJ, et al. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993 Sep; 44(3): 638–42PubMedCrossRef
56.
Curry Jr RC, Roberts WC. Status of the coronary arteries in the nephrotic syndrome: analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated. Am J Med 1977 Aug; 63(2): 183–92PubMedCrossRef
57.
Kasiske BL, Velosa JA, Halstenson CE, et al. The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am J Kidney Dis 1990 Jan; 15(1): 8–15PubMed
58.
Spitalewitz S, Porush JG, Cattran D, et al. Treatment of hyper-lipidemia in the nephrotic syndrome: the effects of pravastatin therapy. Am J Kidney Dis 1993 Jul; 22(1): 143–50PubMed
59.
Rabelink AJ, Hene RJ, Erkelens DW, et al. Effects of simvastatin and cholestyramine on lipoprotein profile in hyper-lipidaemia of nephrotic syndrome. Lancet 1988 Dec 10; II(8624): 1335–8CrossRef
60.
Vega GL, Grundy SM. Lovastatin therapy in nephrotic hyper-lipidemia: effects on lipoprotein metabolism. Kidney Int 1988 Jun; 33(6): 1160–8PubMedCrossRef
61.
Thomas ME, Harris KP, Ramaswamy C, et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 1993 Nov; 44(5): 1124–9PubMedCrossRef
62.
Olbricht CJ, Wanner C, Thiery J, et al. Simvastatin in nephrotic syndrome: Simvastatin in Nephrotic Syndrome Study Group. Kidney Int Suppl 1999 Jul; 71: S113–6PubMedCrossRef
63.
Matzkies FK, Bahner U, Teschner M, et al. Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome. Am J Nephrol 1999; 19(4): 492–4PubMedCrossRef
64.
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 Nov 16; 333(20): 1301–7PubMedCrossRef
65.
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 May 27; 279(20): 1615–22PubMedCrossRef
66.
Tonelli M, Moye L, Sacks FM, et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003 Jun; 14(6): 1605–13PubMedCrossRef
67.
Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003 Mar; 41(3): 565–70PubMedCrossRef
68.
Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 1994 Feb; 45(2): 578–85PubMedCrossRef
69.
70.
Ogi M, Yokoyama H, Tomosugi N, et al. Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am J Kidney Dis 1994 Sep; 24(3): 427–36PubMed
71.
Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997 Apr 4; 46(RR-8): 1–24
72.
Garin EH, Sausville PJ, Richard GA. Impaired primary antibody response in experimental nephrotic syndrome. Clin Exp Immunol 1983 Jun; 52(3): 595–8PubMed
73.
Passerini P, Como G, Vigano E, et al. Idiopathic membranous nephropathy in the elderly. Nephrol Dial Transplant 1993 Dec 1; 8(12): 1321–5PubMed
74.
Lorca E, Ponticelli C. Idiopathic nephrotic syndrome in the elderly. Geriatr Nephrol Urol 1995; 4: 189–95CrossRef
75.
Passerini P, Ponticelli C. Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy. Semin Nephrol 2003 Jul; 23(4): 355–61PubMedCrossRef
76.
Abrass CK. Treatment of membranous nephropathy in the elderly. Semin Nephrol 2003 Jul; 23(4): 373–8PubMedCrossRef
77.
Ponticelli C, Zuchelli P, Passerini P, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989 Jan; 320(1): 8–13PubMedCrossRef
78.
Bizzarri D, Imperiali P, Duranti E, et al. Idiopathic membranous glomerulonephritis in the elderly. Contrib Nephrol 1993; 105: 65–70PubMed
79.
Branten AJW, Reichert LJM, Koene RAP, et al. Oral cyclophosphamide versus chlorambucil in the treatment of patients with idiopathic membranous nephropathy and renal insufficiency. Q J Med 1998 May; 91(5): 359–66CrossRef
80.
Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998 Mar; 9(3): 444–50PubMed
81.
Wetzels JF, Branten AJ, Vervloet MG, et al. Mycophenolate mofetil in membranous nephropathy: a prospective cohort study [abstract]. J Am Soc Nephrol 2005 Nov 1; 16: 531A
82.
Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001 Apr; 59(4): 1484–90PubMedCrossRef
83.
Cattran DC, Greenwood C, Ritchie S, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 1995 Apr; 47(4): 1130–5PubMedCrossRef
84.
Ponticelli C, Villa M. Does ciclosporine have a role in the treatment of membranous nephropathy? Nephrol Dial Transplant 1999 Jan; 14(1): 23–5PubMedCrossRef
85.
Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005 May 26; 352(21): 2211–21PubMedCrossRef
86.
Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006 Feb; 47(2): 233–40PubMedCrossRef
87.
Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003 Jul; 14(7): 1851–7PubMedCrossRef
88.
Rossi P, Demoux AL, Granel B, et al. Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune haemolytic anaemia associated with idiopathic membranous nephropathy [letter]. Rheumatology (Oxford) 2005 Mar; 44(3): 403–5CrossRef
89.
Hall CL. The natural course of gold and penicillamine nephropathy: a long-term study of 54 patients. Adv Exp Med Biol 1989; 252: 247–56PubMedCrossRef
90.
Jefferson JA, Couser WG. Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol 2003 Jul; 23(4): 400–5PubMedCrossRef
91.
Tang S, Lai FM, Lui YH, et al. Lamivudine in hepatitis Bassociated membranous nephropathy. Kidney Int 2005 Oct; 68(4): 1750–8PubMedCrossRef
92.
Lai FM, Tam JS, Li PK, et al. Replication of hepatitis B virus with corticosteroid therapy in hepatitis B virus related membranous nephropathy. Virchows Arch A Pathol Anat Histopathol 1989; 414(3): 279–84PubMedCrossRef
93.
Lai KN, Tam JS, Lin HJ, et al. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 1990; 54(1): 12–7PubMedCrossRef
94.
Perna A, Schieppati A, Zamora J, et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 2004 Sep; 44(3): 385–401PubMed
95.
du Buf-Vereijken PW, Branten AJ, Wetzels JF. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transplant 2004 May; 19(5): 1142–8PubMedCrossRef
96.
Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004 Oct; 17(4): 770–82PubMedCrossRef
Metadata
Title
Membranous Nephropathy in the Older Adult
Epidemiology, Diagnosis and Management
Authors
Dr Jeroen K. J. Deegens
Jack F. M. Wetzels
Publication date
01-09-2007
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 9/2007
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200724090-00002

Other articles of this Issue 9/2007

Drugs & Aging 9/2007 Go to the issue

Review Article

Pharmacological Management of Cancer Pain in the Elderly

Therapy In Practice

Elderly-Onset Systemic Lupus Erythematosus

Short Communication

Bleeding During Enoxaparin Treatment More Common with Age Over 75 Years and Severe Renal Insufficiency

Review Article

A Composite Screening Tool for Medication Reviews of Outpatients

Original Research Article

Determining Therapeutic Approaches in the Elderly with Rectal Cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits